Defendant

Aurolife Pharma LLC

2 cases as defendant.

Cases
2
Active
0
2 closed
Filed
2017–2020
Top venue
D. New Jersey
1 case

Company profile

Aurolife Pharma LLC — commonly shortened to "Aurolife" — is a generic pharmaceutical manufacturer headquartered at 2400 Route 130 North, Dayton, New Jersey (08810), with a second drug-product manufacturing site at 2929 Weck Drive, Durham, North Carolina. It is a Delaware limited liability company and a wholly owned subsidiary of Aurobindo Pharma USA, Inc., which in turn is wholly owned by Aurobindo Pharma Limited, a publicly listed Indian generics company based in Hyderabad (NSE/BSE: AUROPHARMA). Aurolife was incorporated around 2008 and was created specifically to serve Aurobindo's US manufacturing and market needs. Third-party business-data sources give inconsistent size figures — one credit report estimates roughly 200 employees and about $180 million in sales, while ZoomInfo and Salary.com list substantially smaller headcounts (roughly 25–50); no audited standalone figures are public, since Aurolife's results are consolidated into Aurobindo's filings.

Operations. Aurolife is an operating manufacturer and marketer, not a shell or licensing entity. It develops, manufactures, imports, sells, and wholesales generic prescription drugs in the US, prepares and submits Abbreviated New Drug Applications (ANDAs) to the FDA, and holds New Jersey drug-wholesaler registration. Its product lines are generic oral solid-dose and finished-dose pharmaceuticals; it also receives FDA inspection activity at its Durham facility. Aurobindo corporate filings list Aurolife as a 100%-owned subsidiary.

Litigation posture. The tracked data show Aurolife as a defendant in one case and never as a plaintiff — the profile of a defendant operating company, not a patent assertion entity. Its sole tracked appearance, Celgene Corp. v. Hetero Labs Ltd. et al. (D.N.J., filed May 11, 2017), is a Hatch-Waxman ANDA suit brought by brand manufacturer Celgene. Venue is the District of New Jersey — Celgene's home forum (Summit, NJ) — not the plaintiff-friendly Eastern District of Texas.

Notable context. In that consolidated case (No. 2:17-cv-03387), Celgene asserted patents covering Pomalyst (pomalidomide) against Aurolife alongside Aurobindo Pharma Limited, Aurobindo Pharma USA, Eugia Pharma Specialties, and other generics defendants including Hetero, Apotex, Mylan, Breckenridge, and Teva. Celgene alleged infringement under 35 U.S.C. § 271(e)(2) based on the defendants' ANDA submissions; defendants contested infringement and validity. The case terminated via consent judgments beginning in 2021.

Celgene Corp. v. Aurobindo Pharma Ltd. et al.

settled
Docket:
2:20-cv-00315
Filed:
2020-01-08
Terminated:
2021-07-19
Patents:7855217

Celgene sued Aurobindo entities in D.N.J. (2:20-cv-00315), asserting U.S. 7,855,217 among other patents. The case settled on July 15, 2021, and terminated July 19, 2021 (ANDA No. 213885).

Celgene Corp. v. Hetero Labs Ltd. et al.

terminated
Docket:
2:17-cv-03387
Filed:
2017-05-11
Terminated:
2021-08-19
Patents:8828427

Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.